Pharma Landscape Shifts as GSK Unloads Non-Core Brands

With the end of a calendar year comes a flurry of corporate divestitures and acquisitions, designed to improve a company's bottom line going into the next year. Procter & Gamble, for instance, recently sold the PUR brand to Helen of Troy Limited, a "serial acquirer" of P&G brands who, in addition to PUR, owns Infusium23, Pert Plus and Sure.

So no surprise in 2011's 11th hour deal by GlaxoSmithKline to transfer 17 of its North American consumer OTC healthcare brands to a new owner, as was announced by Prestige Brands and GSK. Prestige Brands will acquire brands including Beano, Goody's, Ecotrin, Fiber Choice, Sominex, and Tagamet from GSK for a total of $660 million in cash, with all transactions expected to be completed in the first half of 2012.

For Prestige Brands, the acquisition is the largest in the company's history, following on the heels of their recent acquisitions of five brands from Blacksmith Brands and Dramamine from Johnson & Johnson. The company expects the acquired GSK brands to generate annual corporate revenues of about $600 million, "with an OTC business segment representing 85 percent of revenues and 90 percent of profits," according to Prestige Brands CEO Matthew M. Mannelly.Continue reading...